SCHEMBL25317246

SCHEMBL25317246

Nc1cc2c(cc1F)C(=O)NC2

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK4 Q9HAZ1 3/20 0.46
NTRK1 P04629 2/20 0.46
FLT3 P36888 2/20 0.46
GSK3B P49841 2/20 0.46
DAPK3 O43293 1/20 0.46
PIM1 P11309 1/20 0.46
ROCK1 Q13464 1/20 0.46
GRM5 P41594 4/20 0.44
CA12 O43570 1/20 0.41
CA9 Q16790 1/20 0.41
NTRK2 Q16620 2/20 0.41
DYRK1B Q9Y463 2/20 0.41
TYRO3 Q06418 1/20 0.41
JAK2 O60674 1/20 0.40
MET P08581 1/20 0.40
FGFR1 P11362 1/20 0.40
PRKACA P17612 1/20 0.40
KDR P35968 1/20 0.40
MAP2K2 P36507 1/20 0.40
MAP2K1 Q02750 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3310305 0.93 CLK4 (0.46) CLK4NTRK1FLT3GSK3BDAPK3
SCHEMBL29560109 0.93 CLK4 (0.46) CLK4NTRK1FLT3GSK3BDAPK3
SCHEMBL1079809 0.84 CLK4 (0.51) CLK4NTRK1FLT3GSK3BDAPK3
SCHEMBL3459944 0.84 CA12 (0.47) CLK4NTRK1FLT3GSK3BDAPK3
SCHEMBL21522348 0.78 CLK4 (0.46) CLK4NTRK1FLT3GSK3BDAPK3
SCHEMBL24667579 0.78 CLK4 (0.46) CLK4NTRK1FLT3GSK3BDAPK3
SCHEMBL15187776 0.78 CLK4 (0.62) CLK4NTRK1FLT3GSK3BDAPK3
SCHEMBL28893845 0.77 CA12 (0.56) CLK4NTRK1FLT3GSK3BDAPK3
SCHEMBL32666530 0.75 CA12 (0.54) CLK4NTRK1FLT3GSK3BDAPK3
SCHEMBL17073495 0.75 PARP10 (0.56) GRM5PARP1PARP10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE REDX PHARMA LTD (GB) 2025-04-17 US disclosed
EP-4466071-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) Redx Pharma Limited (GB) 2024-11-27 EP disclosed
CN-118632845-A Modulators of Rho-associated protein kinase (ROCK) 莱德克斯制药有限公司 2024-09-10 CN disclosed
WO-2023139379-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) REDX PHARMA PLC (GB) 2023-07-27 WO disclosed
WO-2023139379-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) REDX PHARMA PLC (GB) 2023-07-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250122173-A1 MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE ROCK1, ROCK2, RHOA CLK4 2040/4885NTRK1 3655/4885FLT3 2655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.